Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

Exclusion Criteria

• •Infratentorial tumor(s), tumor(s) that communicate with the ventricles or intraventricular disease
• •Bilateral non-contiguous gadolinium enhancing tumor
• •Diffuse disease (i.e., any satellite lesions less than 1.5 cm from anticipated location of any catheter tip or less than two satellite lesions)
• •Known or suspected allergy to study medication or iodine
• •Surgical procedure within four weeks of baseline
• •More than one prior chemotherapy regime or chemotherapy within four weeks (nitrosourea-based within six weeks) of baseline
• •Radiation therapy within four weeks of baseline
• •Investigational agent within last 30 days
• •Previous treatment with any chimeric monoclonal antibody
• •HIV positive
• •Evidence of active hepatitis